# Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

> **NCT07629596** · EARLY_PHASE1 · RECRUITING · sponsor: **Circunited BioPharma (Shenzhen) Co., Ltd.** · enrollment: 5 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Autoimmune Hemolytic Anemia (AIHA)

## Interventions

- **DRUG:** Arnovie101 Infusion Intravenous

## Key facts

- **NCT ID:** NCT07629596
- **Lead sponsor:** Circunited BioPharma (Shenzhen) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629596, "Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*